NasdaqCM:EXASBiotechs
A Look at Exact Sciences (EXAS) Valuation Following Record Q3 Results and Raised Guidance
Exact Sciences (EXAS) caught investors’ attention after the company delivered a record third quarter, powered by strong Cologuard and Oncotype DX demand. Management raised its full-year outlook following this momentum.
See our latest analysis for Exact Sciences.
Momentum has clearly returned for Exact Sciences after this series of upbeat developments. The stock has delivered a strong 63.99% share price return over the last three months, and its one-year total shareholder return now sits at...